Strategic Investment and Leadership Transition
Set to Further Propel MaximBio's Growth
ROCKVILLE, Md., July 29,
2024 /PRNewswire/ -- Maxim Biomedical, Inc., one of
the nation's leading end-to-end rapid diagnostic test developers
and manufacturers, has received a new minority investment from CTM
Investments.
CTM Investments is a growth equity vehicle led by Jason Gray focused on investing in companies
that matter and enabling businesses to achieve important goals for
their customers, employees, communities, and owners.
Jason Gray serves as Head of
Investment Team at Pritzker Vlock Capital Management (PVCM).
Investment partners in CTM include Elon Boms, Managing Director at
PVCM and co-founder of LaunchCapital; Cliff
Sirlin, Venture Partner at LaunchCapital and Partner at
BuyBuildFund; Woody Benson, Venture
Partner at PVCM; Meghan FitzGerald,
Founder/CEO at Grey Ghost Capital; and more.
"We are passionate about companies that matter, about
excellently run businesses, and about growth — and MaximBio has all
three. We admire the long history of MaximBio and look forward to
partnering with Jonathan and the team to support the company's
business going forward," said investor Jason Gray.
As part of the shift to the next generation of MaximBio,
Jonathan Maa is transitioning from the role of Chief Operating
Officer to the role of Chief Executive Officer. Previous Chief
Executive Officer and Co-Founder Dr. Joe
Maa will transition to the role of Chief Scientific
Officer.
Jonathan said, "It is my honor to now serve as MaximBio's CEO.
We are proud to partner with some of the world's leading healthcare
companies and government agencies to deliver diagnostic tests for
many of the world's most pressing indications. My goal in bringing
on our new investment partners and in assuming the role of CEO is
all about positioning MaximBio to leverage our core platform to
serve our mission of improving patient outcomes."
Jonathan Maa continued, "Our history is marked by innovation and
excellence, from the early days of HIV diagnostic testing to our
recent achievements in rapidly scaling up COVID test manufacturing
and providing millions of tests in response to the pandemic. We are
committed to building on this legacy in IVD development and
manufacturing for years to come."
Outcome Capital acted as the exclusive strategic and financial
advisor to Maxim Biomedical.
About Maxim Biomedical, Inc.:
Headquartered in
Rockville, MD, and focused on US
manufacturing, Maxim Biomedical® is a leading diagnostic
development and manufacturing company providing innovative
solutions to the global leaders in diagnostic healthcare. Our
mission is to support private and public partners in the creation
of diagnostic products that are affordable, accessible, and enable
actionable testing to improve patient outcomes around the globe.
For more information about MaximBio please visit
https://maximbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/maxim-biomedical-inc-announces-new-minority-investment-partner-and-appoints-jonathan-maa-as-ceo-302208667.html
SOURCE Maxim Biomedical, Inc.